Please assess the completion status of the following clinical trial:

Trial Title: Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with unilateral Ménière's disease (definite or probable, according to Committee on Hearing and Equilibrium guidelines, 1995) with hearing loss and presenting with recurrent vertigo, not responding to medical treatment for at least 6 months will be included. There should be normal, age appropriate hearing in the contralateral ear.~Exclusion Criteria:~* Patients with Ménière's disease in later stages (not having vertigo attacks).~* Age: patients older than 70 years at the start of the trial.~* Severe disability (e.g. neurological, orthopaedic, cardiovascular) or serious concurrent illness that might interfere with treatment or follow up.~* Active additional neuro-otological disorders that may mimic Ménière's disease (e.g. vestibular migraine, vertebro-basilar TIAs, acoustic neuroma) and thus will make the objective follow up difficult.~* Concurrent ear pathology that may interfere with transtympanic treatment (e.g. active middle ear disease).~* Family history of unexplained deafness (possibility of genetic susceptibility to gentamicin toxicity).~* History of known adverse/allergic reaction to steroids or gentamicin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Steroid (Methylprednisolone) (Type: EXPERIMENTAL): Steroid (Methylprednisolone)
- Gentamicin (Type: ACTIVE_COMPARATOR): Gentamicin

Based on this trial design, predict the completion outcome and termination type (if applicable).